Multimodal Prognostic Assessment of Acute Ischemic Stroke Patients With Atrial Fibrillation: a Prospective, Multicenter, Observational Study (IAT-CLOSURE)
Cardiologic work-up: Noninvasive prolonged ECG monitoring with a duration of 7 days measuring AF burden； Echocardiography measuring LA volume or volume index, LA diameter or diameter index； Cardiac CTA measuring LAA morphologies, cardiac thrombus.
Study summary
The main purpose of this study is to investigate the safety and outcomes of different treatment strategies, including best medical therapy (OAC \[oral anticoagulation\], antiplatelet \[APT\]) and left atrial appendage closure \[LAAC\] in acute ischemic stroke (AIS) patients with atrial fibrillation (AF) based on multimodal assessment from combined brain and cardiologic work-up, and to optimize secondary prevention.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Age \> 18 years old；
2. Acute ischemic stroke with onset ≤ 14 days；
3. Previously or during this hospitalization diagnosed with non-valvular atrial fibrillation;
4. Informed consent obtained from the patient or his/her legal representative；
Exclusion Criteria:
1. Pacemaker, implantable cardioverter defibrillator or implantable cardiac monitor;
2. Left atrial appendage has been removed or post occlusion device implantation;
3. Transient AF secondary to other reversible disorders；
4. Life expectancy less than 1 year;
5. Patients that cannot complete subsequent follow-up (e.g. no fixed residence, overseas patients, etc.);
6. Females who are pregnant or in lactation;
7. Participating in other clinical trials that could confound the evaluation of the study;
8. Other circumstances that the investigator considers inappropriate for participation or may pose a significant risk to patients.
Primary outcome measure(s)
Composite endpoints of ischemic stroke, systemic embolism, myocardial infarction, major bleeding (BARC type 3-5) and all-cause mortality — 1 year Stroke only including ischemic stroke
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.